PB Fintech shares fell to a 52-week low of ₹930 as the market reacted to mixed quarterly results and ongoing regulatory concerns. While the company reported strong revenue growth, high advertising costs led to an EBITDA miss, fueling worries about potential insurance commission caps.
Shares of PB Fintech, the parent company of PolicyBazaar, touched a new 52-week low of ₹930 on November 2, 2026. This sharp decline follows a period of significant volatility, as investors weighed the company's latest quarterly performance against long-standing regulatory fears.
Earnings Performance and Margin Pressure
The financial results for the September quarter presented a mixed picture for shareholders. While top-line growth remained robust, with revenue climbing 35% and net profit rising 43% year-on-year, the market reacted to profitability concerns. Total insurance premiums grew by 38%, supported by strong demand for new health insurance products and protection plans. However, profitability metrics fell short of expectations. Adjusted EBITDA reached approximately ₹220 crore, missing analyst estimates. This was largely driven by a 59% jump in advertising and promotional expenses, which kept EBITDA margins stagnant at around 10%.
Regulatory Impact on Revenue Model
The primary driver of the stock’s decline, which has lost over 40% of its value in recent months, is the uncertainty surrounding an IRDAI consultation paper. The regulator has proposed caps on the commissions that insurance intermediaries can earn. Investors are concerned that if these caps are implemented, they could significantly reduce the company’s take rates—the portion of the insurance premium it retains as revenue. Market participants fear that such a change could impact the financial viability of key business segments, such as PB Partners, leading to long-term earnings pressure.
Brokerage Views and Future Outlook
Analyst sentiment remains divided. Some brokerages continue to maintain a 'Buy' rating, betting that the firm’s dominant market position will allow it to adapt its strategy even if regulations tighten. Others have adopted a more cautious approach, lowering their earnings estimates for fiscal years 2027 and 2028. These analysts suggest that the company may face structural challenges in maintaining its previous growth pace if its revenue model is forced to change.
For investors, the immediate focus will be on the final details of the regulator’s decision regarding commission structures. Beyond the regulatory news, the next important updates to track will be the company’s ability to control its heavy advertising spending, its success in diversifying into non-insurance revenue, and whether it can sustain volume growth in the second half of the fiscal year while attempting to improve its operating margins.